Cagrilintide + Semaglutide: Scientific Profile
Publicado el · Actualizado el
A research blend combining cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist). Two lyophilized reference compounds, HPLC purity with COA per batch. Exclusively for research (RUO).
Mechanism of action
This blend brings together two long-acting peptides: cagrilintide, an analog of amylin (a hormone co-secreted with insulin), and semaglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor. Amylin participates in satiety signals and in the regulation of gastric emptying; GLP-1, in glucose-dependent insulin secretion and in central satiety. As reference compounds they are studied together to investigate the interaction of both pathways. Material for research; it is not clinical or dosing guidance for people.
Mechanism summary
Combination of two complementary pathways: amylin (cagrilintide) and GLP-1 (semaglutide). Amylin is associated in the literature with satiety and gastric emptying; GLP-1 with glucose-dependent insulin secretion and satiety. The research interest of the combination lies in the study of incretin and amylinergic pathways jointly versus each component separately.
Clinical Studies (4)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide with Semaglutide 2.4 mg for Weight Management (Enebo, et al. · The Lancet · 2021) PMID 33894838.
- Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg in Type 2 Diabetes: a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial (Frias, et al. · The Lancet · 2023) PMID 37364590.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) (Garvey, et al. · The New England Journal of Medicine · 2025) PMID 40544433.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) (Davies, et al. · The New England Journal of Medicine · 2025) PMID 40544432.
Warnings
Cagrilintide + Semaglutide is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Exclusively for research (RUO). Not suitable for diagnosis or for research in human beings outside a regulated framework.
- Blend of two compounds: no single CAS/formula; see the datasheets for each component.
Technical data
- Compound type
- blend
- Storage
- -20 °C liofilizado; 2-8 °C reconstituido
- Shelf life (lyophilized)
- 24-36 months lyophilized at -20°C
- Shelf life (reconstituted)
- 4-6 weeks reconstituted at 2-8°C
- Light-sensitive
- Sí
Available for research
Cagrilintide + Semaglutide is available as a research reagent (RUO) with HPLC-verified purity:
Frequently asked questions about Cagrilintide + Semaglutide
What is Cagrilintide + Semaglutide?
A research blend combining cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist). Two lyophilized reference compounds, HPLC purity with COA per batch.
What is the mechanism of action of Cagrilintide + Semaglutide?
Combination of two complementary pathways: amylin (cagrilintide) and GLP-1 (semaglutide). Amylin is associated in the literature with satiety and gastric emptying; GLP-1 with glucose-dependent insulin secretion and satiety.
What is Cagrilintide + Semaglutide researched for?
In preclinical research, Cagrilintide + Semaglutide is studied mainly in: Research on combined amylin + GLP-1 pathways; Studies of satiety and gastric emptying; Models of energy metabolism. Material exclusively for scientific research.
How is Cagrilintide + Semaglutide stored?
Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 24-36 meses liofilizado a -20°C; una vez reconstituido: 4-6 semanas reconstituido a 2-8°C; protéjase de la luz.
What administration routes are studied for Cagrilintide + Semaglutide?
In the research models the following are described: Subcutaneous. Use is exclusively for scientific research.
What precautions should be considered with Cagrilintide + Semaglutide?
Cagrilintide + Semaglutide is material exclusively for research. Exclusively for research (RUO). Not suitable for diagnosis or for research in human beings outside of a regulated framework. Blend of two compounds: no unique CAS/formula; see the data sheets of each component.